ATE253914T1 - Farnesyl protein transferase inhibitoren zur behandlung von arthropathien - Google Patents

Farnesyl protein transferase inhibitoren zur behandlung von arthropathien

Info

Publication number
ATE253914T1
ATE253914T1 AT99931230T AT99931230T ATE253914T1 AT E253914 T1 ATE253914 T1 AT E253914T1 AT 99931230 T AT99931230 T AT 99931230T AT 99931230 T AT99931230 T AT 99931230T AT E253914 T1 ATE253914 T1 AT E253914T1
Authority
AT
Austria
Prior art keywords
arthropathies
treatment
protein transferase
transferase inhibitors
farnesyl protein
Prior art date
Application number
AT99931230T
Other languages
English (en)
Inventor
David William Janssen Rese End
Roads
Marina Lucie Louise Cools
Wauwe Jean Pierre Frans Van
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of ATE253914T1 publication Critical patent/ATE253914T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
AT99931230T 1998-07-06 1999-06-30 Farnesyl protein transferase inhibitoren zur behandlung von arthropathien ATE253914T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98202258 1998-07-06
PCT/EP1999/004546 WO2000001386A1 (en) 1998-07-06 1999-06-30 Farnesyl protein transferase inhibitors for treating arthropathies

Publications (1)

Publication Number Publication Date
ATE253914T1 true ATE253914T1 (de) 2003-11-15

Family

ID=8233891

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99931230T ATE253914T1 (de) 1998-07-06 1999-06-30 Farnesyl protein transferase inhibitoren zur behandlung von arthropathien

Country Status (33)

Country Link
US (1) US6451812B1 (de)
EP (1) EP1094815B1 (de)
JP (1) JP4491136B2 (de)
KR (1) KR100674122B1 (de)
CN (1) CN1170538C (de)
AP (1) AP1597A (de)
AT (1) ATE253914T1 (de)
AU (1) AU762470B2 (de)
BG (1) BG64939B1 (de)
BR (1) BR9911869A (de)
CA (1) CA2337800C (de)
CZ (1) CZ302269B6 (de)
DE (1) DE69912790T2 (de)
DK (1) DK1094815T3 (de)
EA (1) EA003510B1 (de)
EE (1) EE04579B1 (de)
ES (1) ES2212580T3 (de)
HR (1) HRP20000904A2 (de)
HU (1) HU229358B1 (de)
ID (1) ID27199A (de)
IL (2) IL140720A0 (de)
MY (1) MY122189A (de)
NO (1) NO318338B1 (de)
NZ (1) NZ509647A (de)
PL (1) PL193296B1 (de)
PT (1) PT1094815E (de)
SI (1) SI1094815T1 (de)
SK (1) SK285231B6 (de)
TR (1) TR200003882T2 (de)
TW (1) TW557212B (de)
UA (1) UA64797C2 (de)
WO (1) WO2000001386A1 (de)
ZA (1) ZA200100152B (de)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20000904A2 (en) 1998-07-06 2001-12-31 Janssen Pharmaceutica Nv Farnesyl protein transferase inhibitors for treating arthropathies
PT1106612E (pt) * 1999-11-30 2004-06-30 Pfizer Prod Inc Derivados de quinolina uteis para inibir a farnesil-proteina-transferase
JO2361B1 (en) 2000-06-22 2006-12-12 جانسين فارماسيوتيكا ان. في Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
DE60118225T2 (de) 2000-09-25 2007-05-03 Janssen Pharmaceutica N.V. Chinolin- und chinazolinderivate und deren verwendung als farnesyl transferase inhibitoren
JP4974437B2 (ja) 2000-09-25 2012-07-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルトランスフェラーゼを阻害する６−［（置換フェニル）メチル］−キノリンおよびキナゾリン誘導体
WO2002024686A2 (en) 2000-09-25 2002-03-28 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives
US7067531B2 (en) 2000-09-25 2006-06-27 Angibaud Patrick Rene Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives
AU2002214056A1 (en) 2000-11-21 2002-06-03 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting benzoheterocyclic derivatives
JP4351445B2 (ja) 2000-12-27 2009-10-28 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルトランスフェラーゼを阻害する４−置換−キノリンおよびキナゾリン誘導体
US20040067968A1 (en) * 2000-12-27 2004-04-08 Angibaud Patrick Rene Farnesyl transferase inhibiting 4-heterocyclyl quinoline and quinazoline
WO2002098370A2 (en) * 2001-03-02 2002-12-12 Medimmune, Inc. Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
WO2003000705A1 (en) * 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel quinolines and uses thereof
EP1408971A4 (de) 2001-06-21 2006-01-25 Ariad Pharma Inc Neue chinoline und ihre verwendungszwecke
EP1458720B1 (de) 2001-12-19 2009-03-18 Janssen Pharmaceutica N.V. Durch c-verbundene imidazole substituierte 1,8-annellierten chinolon-derivate als farnesyl transferase inhibitoren
EP1490065B1 (de) 2002-03-22 2007-06-13 Janssen Pharmaceutica N.V. Benzylimidazolyl substituierte 2-chinolon und chinazolinon derivate zur verwendung als farnesyl transferase inhibitoren
DE60307616T2 (de) 2002-04-15 2007-10-04 Janssen Pharmaceutica N.V. Farnesyl transferase hemmende tricyclische quinazolinederivate substitutiert mit kohlenstoff-gebundenen imidazolen oder triazolen
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US8034831B2 (en) 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
JP4764818B2 (ja) 2003-04-11 2011-09-07 メディミューン，エルエルシー 組換えｉｌ−９抗体およびその使用
EP1660186B1 (de) 2003-08-18 2013-12-25 MedImmune, LLC Humanisierung von antikörpern
JP4691041B2 (ja) 2003-11-20 2011-06-01 チルドレンズ ホスピタル メディカル センター Ｇｔｐアーゼ阻害剤および使用方法
US20060106060A1 (en) * 2004-03-18 2006-05-18 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies (Lansbury)
WO2005089518A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Uch-l1 expression and cancer therapy
US20060121042A1 (en) 2004-10-27 2006-06-08 Medimmune, Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
ES2403060T3 (es) 2004-11-05 2013-05-13 Janssen Pharmaceutica Nv Uso terapéutico de inhibidores de la farnesiltransferasa y métodos de control de la eficacia de los mismos.
US20060194821A1 (en) * 2005-02-18 2006-08-31 The Brigham And Women's Hospital, Inc. Compounds inhibiting the aggregation of superoxide dismutase-1
JP5153613B2 (ja) 2005-03-18 2013-02-27 メディミューン，エルエルシー 抗体のフレームワーク・シャッフル
EP1893647A2 (de) 2005-06-23 2008-03-05 MedImmune, Inc. Antikörperformulierungen mit optimierten aggregations- und fragmentierungsprofilen
WO2007016539A2 (en) 2005-07-29 2007-02-08 Children's Hospital Medical Center Gtpase inhibitors and methods of use and crystal structure of rac-1 gtpase
EP1968591A4 (de) 2005-12-23 2010-02-17 Link Medicine Corp Behandlung von synucleinopathien
ES2439994T3 (es) 2006-08-28 2014-01-27 Kyowa Hakko Kirin Co., Ltd. Anticuerpos antagonistas monoclonales humanos específicos de LIGHT humano
CA2682292A1 (en) 2007-03-30 2008-10-09 Medimmune, Llc Aqueous formulation comprising an anti-human interferon alpha antibody
AU2008256928A1 (en) * 2007-05-23 2008-12-04 Allergan, Inc. Therapeutic ((phenyl)imidazolyl)methylquinolinyl compounds
WO2009151683A2 (en) 2008-03-12 2009-12-17 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
JP2012508768A (ja) 2008-11-13 2012-04-12 リンク・メディスン・コーポレーション アザキノリノン誘導体及びその使用
FR2967353B1 (fr) 2010-11-16 2013-08-16 Centre Nat Rech Scient Derives de quinolinone
US9540443B2 (en) 2011-01-26 2017-01-10 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies
US9980942B2 (en) 2012-05-02 2018-05-29 Children's Hospital Medical Center Rejuvenation of precursor cells
CN116574185A (zh) 2012-07-25 2023-08-11 塞尔德克斯医疗公司 抗kit抗体及其用途
WO2014059028A1 (en) 2012-10-09 2014-04-17 Igenica, Inc. Anti-c16orf54 antibodies and methods of use thereof
ES2619610T3 (es) * 2012-10-16 2017-06-26 Janssen Pharmaceutica Nv Moduladores de ROR-gamma-t de quinolinilo enlazado con heteroarilo
MY189505A (en) * 2012-10-16 2022-02-16 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of roryt
CA2888485C (en) * 2012-10-16 2021-01-26 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of ror.gamma.t
SG11201509982UA (de) 2013-06-06 2016-04-28 Igenica Biotherapeutics Inc
KR102313341B1 (ko) 2013-08-26 2021-10-18 바이오엔테크 리서치 앤드 디벨롭먼트 인코포레이티드 시알릴-루이스 ａ에 대한 사람 항체 코드화 핵산
US9221804B2 (en) * 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
BR112016008215A2 (pt) 2013-10-15 2017-09-26 Janssen Pharmaceutica Nv moduladores de quinolinila ligados por alquila de roryt
US9403816B2 (en) * 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
WO2015057203A1 (en) * 2013-10-15 2015-04-23 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of ror-gamma-t
ES2742843T3 (es) 2013-10-15 2020-02-17 Janssen Pharmaceutica Nv Moduladores de quinolinilo de ROR(gamma)t
US9284308B2 (en) * 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
DK3154583T3 (da) 2014-06-04 2021-03-22 Biontech Res And Development Inc Humane monoklonale antistoffer mod gangliosid gd2
US10028503B2 (en) 2014-06-18 2018-07-24 Children's Hospital Medical Center Platelet storage methods and compositions for same
PL3333191T3 (pl) 2014-12-11 2021-05-04 Pierre Fabre Médicament Przeciwciała przeciwko c10orf54 i ich zastosowania
MX2017011194A (es) 2015-03-03 2018-04-10 Kymab Ltd Anticuerpos, usos y métodos.
HUE044698T2 (hu) 2015-08-17 2019-11-28 Kura Oncology Inc Kezelési módszer rákos páciensek kezelésére farnezil-transzferáz inhibitorokkal
CN114470194A (zh) 2015-12-02 2022-05-13 斯特库伯株式会社 与btn1a1免疫特异性结合的抗体和分子及其治疗用途
KR102815803B1 (ko) 2015-12-02 2025-06-05 주식회사 에스티사이언스 당화된 btla(b- 및 t-림프구 약화인자)에 특이적인 항체
JP2019534290A (ja) 2016-11-03 2019-11-28 クラ オンコロジー， インコーポレイテッド 癌の治療方法において使用するためのファルネシルトランスフェラーゼ阻害剤
EP3534947A1 (de) 2016-11-03 2019-09-11 Kymab Limited Antikörper, kombinationen mit antikörpern, biomarker, verwendungen und verfahren
US12215151B2 (en) 2017-05-31 2025-02-04 Stcube & Co., Inc. Methods of treating cancer using antibodies and molecules that immunospecifically bind to BTN1A1
KR20200015602A (ko) 2017-05-31 2020-02-12 주식회사 에스티큐브앤컴퍼니 Btn1a1에 면역특이적으로 결합하는 항체 및 분자 및 이의 치료적 용도
CN110997724A (zh) 2017-06-06 2020-04-10 斯特库伯株式会社 使用结合btn1a1或btn1a1-配体的抗体和分子治疗癌症的方法
US11707522B2 (en) 2017-10-13 2023-07-25 Boehringer Ingelheim International Gmbh Human antibodies to Tn antigen
KR102767692B1 (ko) 2018-07-20 2025-02-17 피에르 파브르 메디카먼트 Vista의 수용체
CA3151110A1 (en) 2019-08-16 2021-02-25 Children's Hospital Medical Center Methods of treating a subject with a cdc42-specific inhibitor

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602184A (en) 1993-03-03 1997-02-11 The United States Of America As Represented By Department Of Health And Human Services Monoterpenes, sesquiterpenes and diterpenes as cancer therapy
US5574025A (en) * 1994-10-26 1996-11-12 Merck & Co., Inc. Inhibitors of prenyl-protein transferases
US5831004A (en) * 1994-10-27 1998-11-03 Affymax Technologies N.V. Inhibitors of metalloproteases, pharmaceutical compositions comprising same and methods of their use
FR2729390A1 (fr) * 1995-01-18 1996-07-19 Rhone Poulenc Rorer Sa Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
TW349948B (en) 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
DE69620445T2 (de) * 1995-12-08 2002-12-12 Janssen Pharmaceutica N.V., Beerse (imidazol-5-yl)methyl-2-chinolinoderivate als farnesyl protein transferase inhibitoren
CA2251716A1 (en) 1996-04-15 1997-10-23 W. Gillies Mckenna Sensitization of cells to radiation and chemotherapy
WO1998002436A1 (en) * 1996-07-15 1998-01-22 Bristol-Myers Squibb Company Thiadioxobenzodiazepine inhibitors of farnesyl protein transferase
TW591030B (en) * 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
GB2323783A (en) 1997-04-02 1998-10-07 Ferring Bv Group Holdings Inhibitors of farnesyl protein transferase
RU2205831C2 (ru) 1997-04-25 2003-06-10 Янссен Фармацевтика Н.В. Хиназолиноны, ингибирующие фарнезилтрансферазу
CN100525766C (zh) 1997-06-02 2009-08-12 詹森药业有限公司 用作平滑肌细胞增殖抑制剂的（咪唑-5-基）甲基-2-喹啉酮衍生物
CA2294347C (en) 1997-06-17 2008-01-29 Schering Corporation Benzo(5,6)cyclohepta(1,2-b)pyridine derivatives for the inhibition of farnesyl protein transferase
PL193464B1 (pl) 1998-07-06 2007-02-28 Janssen Pharmaceutica Nv Zastosowanie inhibitora białkowej transferazy farnezylowej
HRP20000904A2 (en) 1998-07-06 2001-12-31 Janssen Pharmaceutica Nv Farnesyl protein transferase inhibitors for treating arthropathies
TR200101343T2 (tr) * 1998-08-27 2001-09-21 Pfizer Products Inc. Kansere karşı kullanılan maddeler olarak alkinil-ikame edilmiş kinolin-2-on türevleri
JP5574025B1 (ja) * 2013-06-25 2014-08-20 大日本印刷株式会社 飲料供給系配管の殺菌方法及び装置

Also Published As

Publication number Publication date
IL140720A (en) 2008-08-07
HUP0103670A2 (hu) 2002-02-28
EA200100112A1 (ru) 2001-06-25
DE69912790D1 (de) 2003-12-18
IL140720A0 (en) 2002-02-10
CA2337800A1 (en) 2000-01-13
PL345352A1 (en) 2001-12-17
EP1094815B1 (de) 2003-11-12
NO20010053D0 (no) 2001-01-04
TW557212B (en) 2003-10-11
BR9911869A (pt) 2001-03-27
EA003510B1 (ru) 2003-06-26
HRP20000904A2 (en) 2001-12-31
EP1094815A1 (de) 2001-05-02
JP2002519379A (ja) 2002-07-02
CA2337800C (en) 2007-12-04
NZ509647A (en) 2003-12-19
AP2001002058A0 (en) 2001-03-31
DE69912790T2 (de) 2004-09-23
ZA200100152B (en) 2002-01-07
EE04579B1 (et) 2006-02-15
WO2000001386A1 (en) 2000-01-13
AU4780699A (en) 2000-01-24
KR100674122B1 (ko) 2007-01-26
TR200003882T2 (tr) 2001-06-21
MY122189A (en) 2006-03-31
PL193296B1 (pl) 2007-01-31
BG64939B1 (bg) 2006-10-31
AP1597A (en) 2006-04-26
NO20010053L (no) 2001-03-02
NO318338B1 (no) 2005-03-07
JP4491136B2 (ja) 2010-06-30
BG105110A (en) 2001-11-30
CN1308535A (zh) 2001-08-15
UA64797C2 (uk) 2004-03-15
KR20010052771A (ko) 2001-06-25
HU229358B1 (en) 2013-11-28
PT1094815E (pt) 2004-04-30
CN1170538C (zh) 2004-10-13
DK1094815T3 (da) 2004-03-29
AU762470B2 (en) 2003-06-26
EE200000770A (et) 2002-04-15
SK285231B6 (sk) 2006-09-07
CZ20004778A3 (en) 2001-05-16
US6451812B1 (en) 2002-09-17
HUP0103670A3 (en) 2003-01-28
HK1034450A1 (en) 2001-10-26
ID27199A (id) 2001-03-08
CZ302269B6 (cs) 2011-01-19
ES2212580T3 (es) 2004-07-16
SK19872000A3 (sk) 2001-08-06
SI1094815T1 (en) 2004-04-30

Similar Documents

Publication Publication Date Title
ATE253914T1 (de) Farnesyl protein transferase inhibitoren zur behandlung von arthropathien
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
DE69910368D1 (de) Pyrazolopyrimidinone cgmp pde5 inhibitoren zur behandlung von sexualfunktionsstörungen
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
ATE275145T1 (de) Chinazolinderivate zur behandlung von tumoren
ATE235481T1 (de) Substituierte benzopyranderivate zur behandlung von entzündungen
DE69934877D1 (de) Biochanin-angereicherter extrakt zur behandlung von estrogenabhängigen erkrankungen
DE69836915D1 (de) Mundpflegemittel zur behandlung von übelriechendem atem
DE69924750D1 (de) Gerät zur thermischen behandlung von gewebe
DE69925306D1 (de) Behandlung von kohlenwasserstoffgas
DE69928542D1 (de) 5ht2-agoniste zur behandlung des glaukoms
DE69806579D1 (de) Anlage zur behandlung von nahrungsmitteln
DE69833699D1 (de) Gefässverschliessende Vorrichtung zur Behandlung von Aneurismen
NO983892D0 (no) Inhibitorer for farnesyl-proteintransferase
DE69936890D1 (de) Vorrichtung zur Behandlung von Ischämie
DE60019158D1 (de) Neue oxabispidin-verbindungen zur behandlung von herzarrhythmien
DE60136477D1 (de) Retinoide zur behandlung von emphysem
ATE279386T1 (de) Retinoide zur behandlung von emphysem
ATE312079T1 (de) Nichtnukleoside reverse transkriptase-hemmer zur behandlung von hiv-infektion
DE69943089D1 (de) Methode zur behandlung von staphylokokkeninfektionen
DE60031790D1 (de) Rar-gamma selektive retinoid-agonisten zur behandlung von emphysemen
DE69807466D1 (de) Triptolid-derivate nützlich zur behandlung von autoimmunkrankheiten
ATE347372T1 (de) Vakzine zur behandlung von mycosen
ATE273276T1 (de) Cyclobutendion-derivate zur behandlung von artherosclerose

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1094815

Country of ref document: EP